Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Sustained-release fampridine for symptomatic treatment of multiple sclerosis.

Korenke AR, Rivey MP, Allington DR.

Ann Pharmacother. 2008 Oct;42(10):1458-65. doi: 10.1345/aph.1L028. Epub 2008 Sep 9. Review.

PMID:
18780812
2.
3.
4.

Sustained release oral fampridine in the treatment of multiple sclerosis.

Kachuck NJ.

Expert Opin Pharmacother. 2009 Aug;10(12):2025-35. doi: 10.1517/14656560903075994. Review. Erratum in: Expert Opin Pharmacother. 2009 Oct;10(14):2393.

PMID:
19586420
5.

Fampridine-SR for multiple sclerosis and spinal cord injury.

Hayes KC.

Expert Rev Neurother. 2007 May;7(5):453-61. Review.

PMID:
17492896
6.

Sustained-release fampridine for multiple sclerosis.

Bever CT, Judge SI.

Expert Opin Investig Drugs. 2009 Jul;18(7):1013-24. doi: 10.1517/13543780903002082. Review. Erratum in: Expert Opin Investig Drugs. 2009 Aug;18(8):1241.

PMID:
19548855
7.

Dose comparison trial of sustained-release fampridine in multiple sclerosis.

Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F202 Study Group.

Neurology. 2008 Oct 7;71(15):1134-41. doi: 10.1212/01.wnl.0000326213.89576.0e. Epub 2008 Jul 30.

PMID:
18672472
8.

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR.

Mult Scler. 2007 Apr;13(3):357-68. Epub 2007 Jan 29.

PMID:
17439905
9.

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.

Cornblath DR, Bienen EJ, Blight AR.

Clin Ther. 2012 May;34(5):1056-69. doi: 10.1016/j.clinthera.2012.03.007. Epub 2012 Apr 11. Review.

PMID:
22497693
10.

Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.

Fernandez O, Berger T, Hartung HP, Putzki N.

Expert Rev Clin Pharmacol. 2012 Nov;5(6):649-65. doi: 10.1586/ecp.12.59. Epub 2012 Nov 13.

PMID:
23146002
11.

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.

Dunn J, Blight A.

Curr Med Res Opin. 2011 Jul;27(7):1415-23. doi: 10.1185/03007995.2011.583229. Epub 2011 May 20. Review.

PMID:
21595605
12.

Dalfampridine: a new agent for symptomatic management of multiple sclerosis.

McDonald S, Clements JN.

Am J Health Syst Pharm. 2011 Dec 15;68(24):2335-40. doi: 10.2146/ajhp110134. Review. Erratum in: Am J Health Syst Pharm. 2012 Apr 1;69(7):544.

PMID:
22135060
13.

Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.

Hayes KC, Potter PJ, Hansebout RR, Bugaresti JM, Hsieh JT, Nicosia S, Katz MA, Blight AR, Cohen R.

Clin Neuropharmacol. 2003 Jul-Aug;26(4):185-92.

PMID:
12897638
14.

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.

Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD.

Neurology. 1997 Apr;48(4):817-21.

PMID:
9109861
15.

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, Fabjan TH, Fazekas F, Fuchs S, Havrdova E, Ledinek AH, Illes Z, Jazbec SS, Klimova E, Komoly S, Kurca E, Linnebank M, Lisy L, Mares J, Prochazkova L, Csilla R, Szilasiova J, Stourac P, Talab R, Turcani P, Vachova M, Vecsei L, Vodusek D, Zapletalova O, Berger T.

CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101.

PMID:
23607697
16.

Dalfampridine: a medication to improve walking in patients with multiple sclerosis.

Pikoulas TE, Fuller MA.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1010-5. doi: 10.1345/aph.1Q714. Epub 2012 Jul 3. Review.

PMID:
22764324
17.

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators.

Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.

PMID:
19249634
18.

[Aminopyridines for symptomatic treatment of multiple sclerosis].

Jensen HB, Stenager E, Ravnborg MH.

Ugeskr Laeger. 2011 Dec 12;173(50):3259-63. Danish.

PMID:
22153210
19.

The use of 4-aminopyridine (fampridine) in demyelinating disorders.

Hayes KC.

CNS Drug Rev. 2004 Winter;10(4):295-316. Review.

20.

Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.

Smith W, Swan S, Marbury T, Henney H 3rd.

J Clin Pharmacol. 2010 Feb;50(2):151-9. doi: 10.1177/0091270009344857. Epub 2009 Dec 4.

PMID:
19966074

Supplemental Content

Support Center